Sigma Healthcare Limited

OTCPK:SIGG.F Stock Report

Market Cap: US$2.0b

Sigma Healthcare Valuation

Is SIGG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SIGG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SIGG.F ($0.92) is trading below our estimate of fair value ($6.34)

Significantly Below Fair Value: SIGG.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SIGG.F?

Other financial metrics that can be useful for relative valuation.

SIGG.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA99.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SIGG.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SIGG.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.4x
PDCO Patterson Companies
0.3x3.0%US$1.9b
AHCO AdaptHealth
0.4x4.8%US$1.4b
OMI Owens & Minor
0.1x4.3%US$991.5m
PETQ PetIQ
0.8x4.9%US$926.6m
SIGG.F Sigma Healthcare
0.9x17.7%US$3.0b

Price-To-Sales vs Peers: SIGG.F is expensive based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.4x).

Price to Earnings Ratio vs Industry

How does SIGG.F's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.8%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.8%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: SIGG.F is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Healthcare industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is SIGG.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SIGG.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SIGG.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SIGG.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.86
0%
20.5%US$1.10US$0.54n/a7
Oct ’25n/a
US$0.86
0%
20.5%US$1.10US$0.54n/a7
Sep ’25n/a
US$0.74
0%
18.4%US$0.91US$0.51n/a8
Aug ’25n/a
US$0.74
0%
18.4%US$0.91US$0.51n/a8
Jul ’25n/a
US$0.73
0%
16.3%US$0.86US$0.51n/a8
Jun ’25n/a
US$0.73
0%
16.3%US$0.86US$0.51n/a8
May ’25n/a
US$0.73
0%
16.9%US$0.85US$0.51n/a8
Apr ’25n/a
US$0.73
0%
16.9%US$0.85US$0.51n/a8
Mar ’25n/a
US$0.58
0%
10.0%US$0.70US$0.51n/a8
Feb ’25n/a
US$0.58
0%
10.0%US$0.70US$0.51n/a8
Jan ’25n/a
US$0.56
0%
6.6%US$0.61US$0.49n/a8
Dec ’24n/a
US$0.54
0%
5.0%US$0.58US$0.49n/a8
Nov ’24n/a
US$0.53
0%
5.4%US$0.58US$0.48n/a7
Oct ’24n/a
US$0.53
0%
5.4%US$0.58US$0.48n/a7
Sep ’24n/a
US$0.55
0%
4.2%US$0.60US$0.54n/a7
Aug ’24n/a
US$0.55
0%
4.2%US$0.60US$0.54n/a7
Jul ’24n/a
US$0.54
0%
11.7%US$0.61US$0.39n/a8
Jun ’24n/a
US$0.37
0%
15.1%US$0.42US$0.25n/a8
May ’24n/a
US$0.39
0%
15.9%US$0.44US$0.25n/a7
Apr ’24n/a
US$0.39
0%
12.7%US$0.43US$0.29n/a8
Mar ’24n/a
US$0.38
0%
14.3%US$0.45US$0.28n/a8
Feb ’24n/a
US$0.38
0%
14.3%US$0.45US$0.28n/a8
Jan ’24n/a
US$0.38
0%
14.3%US$0.45US$0.28n/a8
Dec ’23n/a
US$0.38
0%
14.3%US$0.45US$0.28n/a8
Nov ’23n/a
US$0.38
0%
14.3%US$0.45US$0.28n/a8
Oct ’23n/a
US$0.38
0%
14.3%US$0.45US$0.28n/a8

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y